Coya Therapeutics' (COYA) Buy Rating Reiterated at D. Boral Capital

Key Points

• D. Boral Capital reiterated a "Buy" on Coya with a $15 price target, implying about a 231% upside from the prior close.
• Analyst sentiment is mixed but tilted positive: five analysts rate COYA a Buy and one a Sell, giving an average target of $16 and an overall "Moderate Buy" consensus.
• COYA trades around $4.53 (52‑week range $3.71–$7.75, market cap ≈ $106M) and remains unprofitable after reporting Q results of ($0.34) EPS (miss) and $3.96M revenue (beat), with a negative net margin and a -1.15 EPS forecast for the year.

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at D. Boral Capital in a research note issued on Friday,Benzinga reports. They presently have a $15.00 price target on the stock. D. Boral Capital's target price indicates a potential upside of 231.13% from the stock's previous close.

Several other research firms have also recently weighed in on COYA. HC Wainwright reissued a "buy" rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research report on Monday, March 23rd. Wall Street Zen cut shares of Coya Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, March 21st. Chardan Capital restated a "buy" rating and issued a $14.00 price target on shares of Coya Therapeutics in a research report on Monday, March 16th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Coya Therapeutics in a report on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $16.00.

Coya Therapeutics Stock Performance

Coya Therapeutics stock opened at $4.53 on Friday. Coya Therapeutics has a 52 week low of $3.71 and a 52 week high of $7.75. The firm has a market capitalization of $106.26 million, a PE ratio of -3.57 and a beta of 0.51. The business's 50-day simple moving average is $4.56 and its 200-day simple moving average is $5.33.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last announced its earnings results on Monday, March 16th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.26). The business had revenue of $3.96 million for the quarter, compared to the consensus estimate of $1.93 million. Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%. Research analysts forecast that Coya Therapeutics will post -1.15 earnings per share for the current year.

Institutional Investors Weigh In On Coya Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Alyeska Investment Group L.P. acquired a new position in shares of Coya Therapeutics in the 4th quarter valued at $4,640,000. AWM Investment Company Inc. bought a new stake in Coya Therapeutics in the fourth quarter valued at about $4,205,000. Private Management Group Inc. bought a new stake in Coya Therapeutics in the fourth quarter valued at about $1,626,000. Marshall Wace LLP raised its position in Coya Therapeutics by 438.8% in the fourth quarter. Marshall Wace LLP now owns 225,358 shares of the company's stock worth $1,307,000 after purchasing an additional 183,533 shares in the last quarter. Finally, Dauntless Investment Group LLC raised its position in Coya Therapeutics by 199.5% in the third quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company's stock worth $872,000 after purchasing an additional 101,932 shares in the last quarter. Institutional investors own 39.75% of the company's stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc NASDAQ: COYA is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company's scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya's pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.